Key Drivers
- Very high gross margin
- Positive operating cashflow
- Extremely high leverage
AIAI Summary
ATEC has moved from a pure R&D story to a scaling spine-platform evidenced by durable ~70% gross margins and recent positive operating cash flow/quarterly EBITDA, validating that topline commercialization (Valence, mechanized arm, OsteoAdapt) can drive margin leverage. However, extreme financial leverage (~$596M debt vs ~$12M equity) and high SG&A/R&D mean only tactical accumulation upon consecutive quarter-over-quarter EBITDA/FCF improvement and a clear deleveraging plan is prudent, otherwise downside risk is magnified.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Very high gross margin
- •Positive operating cashflow
- •Extremely high leverage
ATEC combines very high gross margins and positive operating cash flow with outsized operating losses and extreme leverage that leave equity precariously thin and earnings unable to justify the market valuation.
Price Behavior
Key Price Behavior Insights:
- •Mild downtrend
- •Tight consolidation
- •Below moving average
Over the last month the stock has drifted mildly lower into a short-term consolidation below its ~$12.96 moving average, closing at $12.38 and holding near $12.20–$12.50 support while facing resistance around $13.90–$14.70.
Remains far below
Sentiment & News
Key News Insights:
- •Strong margins
- •Product momentum
- •Insider selling
Alphatec reported stronger-than-expected Q4 and FY25 results with improving margins and product momentum (Valence robot) but faces investor repositioning and questions on 2026 growth sustainability.
The beat and margin gains should support valuation upside near term, though investor repositioning and growth-sustainability concerns may add volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings